Update on the pathologic diagnosis of malignant mesothelioma (2024)

1. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC, 2015. [PubMed] [Google Scholar]

2. Husain AN, Colby TV, Ordonez NG, et al.Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.Arch Pathol Lab Med2009;133:1317-31. [PubMed] [Google Scholar]

3. Husain AN, Colby T, Ordonez N, et al.Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.Arch Pathol Lab Med2013;137:647-67. 10.5858/arpa.2012-0214-OA [PubMed] [CrossRef] [Google Scholar]

4. Husain AN, Colby TV, Ordonez NG, et al.Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group . Arch Pathol Lab Med2018;142:89-108. 10.5858/arpa.2017-0124-RA [PubMed] [CrossRef] [Google Scholar]

5. Nicholson AG, Sauter JL, Nowak AK, et al.EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.J Thorac Oncol2020;15:29-49. 10.1016/j.jtho.2019.08.2506 [PubMed] [CrossRef] [Google Scholar]

6. Chaouche-Mazouni S, Scherpereel A, Zaamoum R, et al.Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.Ann Diagn Pathol2015;19:193-7. 10.1016/j.anndiagpath.2015.03.007 [PubMed] [CrossRef] [Google Scholar]

7. Ohta Y, Sasaki Y, Saito M, et al.Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma.Int J Surg Pathol2013;21:493-501. 10.1177/1066896913491320 [PubMed] [CrossRef] [Google Scholar]

8. Ordóñez NG. Value of claudin-4 immunostaining in the diagnosis of mesothelioma.Am J Clin Pathol2013;139:611-9. 10.1309/AJCP0B3YJBXWXJII [PubMed] [CrossRef] [Google Scholar]

9. Kushitani K, Amatya VJ, Okada Y, et al.Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.Histopathology2017;70:375-84. 10.1111/his.13073 [PubMed] [CrossRef] [Google Scholar]

10. Tsuji S, Washimi K, Kageyama T, et al.HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.Sci Rep2017;7:45768. 10.1038/srep45768 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Matsuura R, Kaji H, Tomioka A, et al.Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.Sci Rep2018;8:14251. 10.1038/s41598-018-32534-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Chapel DB, Churg A, Santoni-Rugiu E, et al.Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.Lung Cancer2019;127:69-75. 10.1016/j.lungcan.2018.11.032 [PubMed] [CrossRef] [Google Scholar]

13. Nasu M, Emi M, Pastorino S, et al.High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.J Thorac Oncol2015;10:565-76. 10.1097/JTO.0000000000000471 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Yoshimura M, Kinoshita Y, Hamasaki M, et al.Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours.Histopathology2017;71:1011-4. 10.1111/his.13321 [PubMed] [CrossRef] [Google Scholar]

15. Sheffield BS, Hwang HC, Lee AF, et al.BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.Am J Surg Pathol2015;39:977-82. 10.1097/PAS.0000000000000394 [PubMed] [CrossRef] [Google Scholar]

16. McGregor SM, Dunning R, Hyjek E, et al.BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.Hum Pathol2015;46:1670-8. 10.1016/j.humpath.2015.06.024 [PubMed] [CrossRef] [Google Scholar]

17. Carbone M, Yang H, Pass HI, et al.BAP1 and cancer.Nat Rev Cancer2013;13:153-9. 10.1038/nrc3459 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Righi L, Duregon E, Vatrano S, et al.BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.J Thorac Oncol2016;11:2006-17. 10.1016/j.jtho.2016.06.020 [PubMed] [CrossRef] [Google Scholar]

19. Wu D, Hiroshima K, Yusa T, et al.Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.Ann Diagn Pathol2017;26:31-7. 10.1016/j.anndiagpath.2016.10.010 [PubMed] [CrossRef] [Google Scholar]

20. Hwang HC, Sheffield BS, Rodriguez S, et al.Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.Am J Surg Pathol2016;40:120-6. 10.1097/PAS.0000000000000529 [PubMed] [CrossRef] [Google Scholar]

21. Cigognetti M, Lonardi S, Fisogni S, et al.BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.Mod Pathol2015;28:1043-57. 10.1038/modpathol.2015.65 [PubMed] [CrossRef] [Google Scholar]

22. Berg KB, Dacic S, Miller C, et al.Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.Arch Pathol Lab Med2018;142:1549-53. 10.5858/arpa.2018-0273-OA [PubMed] [CrossRef] [Google Scholar]

23. Hwang HC, Pyott S, Rodriguez S, et al.BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.Am J Surg Pathol2016;40:714-8. 10.1097/PAS.0000000000000616 [PubMed] [CrossRef] [Google Scholar]

24. Kinoshita Y, Hida T, Hamasaki M, et al.A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.Cancer Cytopathol2018;126:54-63. 10.1002/cncy.21928 [PubMed] [CrossRef] [Google Scholar]

25. Hamasaki M, Kinoshita Y, Yoshimura M, et al.Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma.Histopathology2019;75:153-5. 10.1111/his.13872 [PubMed] [CrossRef] [Google Scholar]

26. Hida T, Hamasaki M, Matsumoto S, et al.Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.Lung Cancer2017;104:98-105. 10.1016/j.lungcan.2016.12.017 [PubMed] [CrossRef] [Google Scholar]

27. Chapel DB, Schulte JJ, Berg K, et al.MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.Mod Pathol2020;33:245-54. 10.1038/s41379-019-0310-0 [PubMed] [CrossRef] [Google Scholar]

28. Chapel DB, Husain AN, Krausz T. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.Mod Pathol2019;32:376-86. 10.1038/s41379-018-0159-7 [PubMed] [CrossRef] [Google Scholar]

29. Berg KB, Churg A. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.Am J Surg Pathol2017;41:1221-5. 10.1097/PAS.0000000000000825 [PubMed] [CrossRef] [Google Scholar]

30. Mawas AS, Amatya VJ, Kushitani K, et al.MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.Sci Rep2018;8:134. 10.1038/s41598-017-18545-x [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Amatya VJ, Kushitani K, Mawas AS, et al.MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.Mod Pathol2017;30:672-81. 10.1038/modpathol.2016.181 [PubMed] [CrossRef] [Google Scholar]

32. Travis WD. Sarcomatoid neoplasms of the lung and pleura.Arch Pathol Lab Med2010;134:1645-58. [PubMed] [Google Scholar]

33. Doyle LA, Vivero M, Fletcher CD, et al.Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.Mod Pathol2014;27:390-5. 10.1038/modpathol.2013.164 [PubMed] [CrossRef] [Google Scholar]

34. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.Am J Surg Pathol2007;31:509-20. 10.1097/01.pas.0000213393.57322.c7 [PubMed] [CrossRef] [Google Scholar]

35. Antonescu CR, Suurmeijer AJ, Zhang L, et al.Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.Am J Surg Pathol2015;39:957-67. 10.1097/PAS.0000000000000404 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Anderson T, Zhang L, Hameed M, et al.Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions.Am J Surg Pathol2015;39:132-9. 10.1097/PAS.0000000000000346 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. van de Rijn M, Barr FG, Xiong QB, et al.Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features.Am J Surg Pathol1999;23:106-12. 10.1097/00000478-199901000-00012 [PubMed] [CrossRef] [Google Scholar]

38. Kadota K, Suzuki K, Colovos C, et al.A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.Mod Pathol2012;25:260-71. 10.1038/modpathol.2011.146 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Rosen LE, Karrison T, Ananthanarayanan V, et al.Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.Mod Pathol2018;31:598-606. 10.1038/modpathol.2017.170 [PubMed] [CrossRef] [Google Scholar]

40. Vigneswaran WT, Kircheva DY, Ananthanarayanan V, et al.Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.Ann Thorac Surg2017;103:962-6. 10.1016/j.athoracsur.2016.08.063 [PubMed] [CrossRef] [Google Scholar]

41. Galateau Salle F, Le Stang N, Nicholson AG, et al.New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.J Thorac Oncol2018;13:1189-203. 10.1016/j.jtho.2018.04.023 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

42. Dacic S, Le Stang N, Husain A, et al.Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.Mod Pathol2020;33:255-62. 10.1038/s41379-019-0320-y [PubMed] [CrossRef] [Google Scholar]

43. Brcic L, Vlacic G, Quehenberger F, et al.Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.Arch Pathol Lab Med2018;142:747-52. 10.5858/arpa.2017-0295-OA [PubMed] [CrossRef] [Google Scholar]

44. Salle FG, Le Stang N, Tirode F, et al.Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.J Thorac Oncol2020;15:1037-53. 10.1016/j.jtho.2020.01.025 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Churg A, Hwang H, Tan L, et al.Malignant mesothelioma in situ.Histopathology2018;72:1033-8. 10.1111/his.13468 [PubMed] [CrossRef] [Google Scholar]

46. Churg A, Galateau-Salle F, Roden AC, et al.Malignant mesothelioma in situ: morphologic features and clinical outcome.Mod Pathol2020;33:297-302. 10.1038/s41379-019-0347-0 [PubMed] [CrossRef] [Google Scholar]

47. Minami K, Jimbo N, Tanaka Y, et al.Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.Virchows Arch2020;476:469-73. 10.1007/s00428-019-02674-x [PubMed] [CrossRef] [Google Scholar]

Update on the pathologic diagnosis of malignant mesothelioma (2024)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Msgr. Refugio Daniel

Last Updated:

Views: 5293

Rating: 4.3 / 5 (74 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Msgr. Refugio Daniel

Birthday: 1999-09-15

Address: 8416 Beatty Center, Derekfort, VA 72092-0500

Phone: +6838967160603

Job: Mining Executive

Hobby: Woodworking, Knitting, Fishing, Coffee roasting, Kayaking, Horseback riding, Kite flying

Introduction: My name is Msgr. Refugio Daniel, I am a fine, precious, encouraging, calm, glamorous, vivacious, friendly person who loves writing and wants to share my knowledge and understanding with you.